Source comparison
Quickcomparison
Dose Range GHRH (1-29) 100–300 mcg Sermorelin Frequency Once daily Administration Subcutaneous injection Cycle Length 8-12 weeks 12+ weeks Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3 or FDA approved) Moderate human trials (Phas
This comparison does not assign a generated winner or score.
- Dose Range
- GHRH (1-29)
- 100–300 mcg
- Sermorelin
- Frequency
- Once daily
- Administration
- Subcutaneous injection
- Cycle Length
- 8-12 weeks
- 12+ weeks
- Onset Speed
- Moderate (1-2 weeks)
- Evidence Level
- Strong human trials (Phase 3 or FDA approved)
- Moderate human trials (Phase 1-2)
- Efficacy